March round-up of pharma/biotech M&A activity

6 April 2016
mergers-acquisitions-big

Talk about the potential mega-merger between Pfizer (NYSE: PFE) and Allergan (NYSE: AGN) – the biggest proposed deal in pharma history – and whether it will or won’t happen, has inevitably gained enormous attention in the wider world.

But a lot more went on in the world of mergers and acquisitions in pharma and biotech in March.

The month began with news that French orphan oncology Onxeo (Euronext Paris: ONXEO) had agreed to buy DNA Therapeutics, a privately-held, clinical-stage French biopharmaceutical company, for its signal-interfering DNA (siDNA) repair technology, which is directed at overcoming cancer resistance mechanisms.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical